FDA Clearance Tracker · P090012
MELAFIND
Last checked: Nov 20, 2026Latest source record: Nov 1, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Nov 1, 2011
Approved (reclassified)
Time to decision
881 days
Received Jun 3, 2009. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P090012
- Device name
- MELAFIND
- Applicant
- Strata Skin Sciences, Inc.
- Applicant location
- Horsham, PA
- Received
- Jun 3, 2009
- Decided
- Nov 1, 2011
- Decision
- Approved (reclassified)
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 11 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 878.1820
- Specialty
- General & Plastic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE MELAFIND DEVICE. MELAFIND IS INTENDED FOR USE ON CLINICALLY ATYPICAL CUTANEOUS PIGMENTED LESIONS WITH ONE OR MORE CLINICAL OR HISTORICAL CHARACTERISTICS OF MELANOMA, EXCLUDING THOSE WITH A CLINICAL DIAGNOSIS OF MELANOMA OR LIKELY MELANOMA. MELAFIND IS DESIGNED TO BE USED WHEN A DERMATOLOGIST CHOOSES TO OBTAIN ADDITIONAL INFORMATION FOR A DECISION TO BIOPSY. MELAFIND SHOULD NOT BE USED TO CONFIRM A CLINICAL DIAGNOSIS OF MELANOMA. MELAFIND IS ONLY FOR USE BY PHYSICIANS TRAINED IN THE CLINICAL DIAGNOSIS AND MANAGEMENT OF SKIN CANCER (I.E., DERMATOLOGISTS) WHO HAVE ALSO SUCCESSFULLY COMPLETED A TRAINING PROGRAM IN THE APPROPRIATE USE OF MELAFIND.THE MELAFIND RESULT IS ONE ELEMENT OF THE OVERALL CLINICAL ASSESSMENT. MELAFIND POSITIVE LESIONS (WHICH MAY INCLUDE MALIGNANT MELANOMA, MELANOMA IN SITU, HIGH GRADE DYSPLASTIC NEVI AND ATYPICAL MELANOCYTIC PROLIFERATION/HYPER-PLASIA) SHOULD BE CONSIDERED FOR BIOPSY; THE BIOPSYDECISION OF A MELAFIND NEGATIVE LESION SHOULD BE BASED ON THE REMAINDER OF THE ENTIRE CLINICAL CONTEXT. LESIONS THAT ARE "NON-EVALUABLE" BY MELAFIND SHOULD BE CAREFULLY RE-EVALUATED FOR BIOPSY.MELAFIND IS INDICATED ONLY FOR USE ON LESIONS WITH A DIAMETER BETWEEN 2 MM AND 22 MM, LESIONS THAT ARE ACCESSIBLE BY THE MELAFIND IMAGER, LESIONS THAT ARE SUFFICIENTLY PIGMENTED (I.E. NOT FOR USE ON NON-PIGMENTED OR SKIN-COLORED LESIONS), LESIONS THAT DO NOT CONTAIN A SCAR ORFIBROSIS CONSISTENT WITH PREVIOUS TRAUMA, LESIONS WHERE THE SKIN IS INTACT (LE., NON-ULCERATED OR NON-BLEEDING LESIONS), LESIONS GREATER THAN 1 CM AWAY FROM THE EYE, LESIONS WHICH DO NOT CONTAIN FOREIGN MATTER, AND LESIONS NOT ON SPECIAL ANATOMIC SITES (IE., NOT FOR USE ON ACRAL,PALMAR, PLANTAR, MUCOSAL, OR SUBUNGUAL AREAS). MELAFIND IS NOT DESIGNED TO DETECT PIGMENTED NON-MELANOMA SKIN CANCERS, SO THE DERMATOLOGIST SHOULD RELY ON CLINICAL EXPERIENCE TO DIAGNOSE SUCH LESIONS.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OYD (Optical diagnostic device for melanoma detection).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Strata Skin Sciences, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K193478 · Decided Jan 14, 2020 · 29 days after receipt
Device type: Powered Laser Surgical Instrument (GEX) · General & Plastic Surgery
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.